The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Pharmaceutical CDMO Market Research Report 2025

Global Pharmaceutical CDMO Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1902644

No of Pages : 107

Ask Your Query
Synopsis
A CDMO is a company dedicated to providing drug development and manufacturing services for the pharmaceutical and biotechnology industries. CDMO activities can broadly be divided into four fields: product development, manufacture of active pharmaceutical ingredients (API), manufacture of finished dosage forms (FDF) and pharma packaging.
Contract Pharmaceutical Manufacturing is part of CDMO, refers to accept commissioned from pharmaceutical companies, provide the service about API production, FDF production, packaging.
Pharmaceutical companies are likely to outsource a wide range of manufacturing related activities including – primary and secondary packaging, formulation, active ingredient manufacturing, labeling, clinical supplies, sterilization, manufacturing of chemical intermediates, etc. CDMOs support pharmaceutical companies at all stages of the process of making medicines: by providing services in the research and development stages, by offering support in manufacturing, and by providing formulating and finishing processes.
The global Pharmaceutical CDMO market was valued at US$ 128270 million in 2023 and is anticipated to reach US$ 217220 million by 2030, witnessing a CAGR of 7.7% during the forecast period 2024-2030.
The key service providers of the Pharmaceutical CDMO in the world are Lonza, Catalent, Thermo Fisher Scientific, Samsung Biologics, Fareva, WuXi AppTech, WuXi Biologics and Siegfried, among which the market share of the top three service providers exceeds 10%, and Lonza is the largest service provider. The services provided by global pharmaceutical CDMO are mainly distributed in North America, Europe and China, among which the top three regions account for nearly 60% of the market share, and North America is currently the largest service provider. In terms of its service type, the growth rate of FDF CDMO is relatively fast. At present, the market share of API CDMO is the highest, more than 40%, followed by FDF CDMO, packaging CDMO and clinical CDMO. In terms of its application, pharmaceutical company are the largest application field, with a market share of more than 60%, followed by biotechnology company.
This report aims to provide a comprehensive presentation of the global market for Pharmaceutical CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmaceutical CDMO.
Report Scope
The Pharmaceutical CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pharmaceutical CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pharmaceutical CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza
Catalent
Thermo Fisher Scientific
Samsung Biologics
Fareva
WuXi AppTech
WuXi Biologics
Siegfried
FUJIFILM Diosynth Biotechnologies
Asymchem
Pfizer CentreOne
Delpharm
Recipharm
AGC Pharma Chemicals
Boehringer Ingelheim
Vetter
Curia
Aenova
Porton
Piramal
Strides Pharma
NextPharma
Famar
Jubilant
Alcami
Euroapi
Eurofins
Avid Bioservices
BioVectra
CPL
Segment by Type
API CDMO
FDF CDMO
Packaging CDMO
Clinical CDMO
Segment by Application
Pharmaceutical Company
Biotechnology Company
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pharmaceutical CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Pharmaceutical CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 API CDMO
1.2.3 FDF CDMO
1.2.4 Packaging CDMO
1.2.5 Clinical CDMO
1.3 Market by Application
1.3.1 Global Pharmaceutical CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical Company
1.3.3 Biotechnology Company
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Pharmaceutical CDMO Market Perspective (2019-2030)
2.2 Pharmaceutical CDMO Growth Trends by Region
2.2.1 Global Pharmaceutical CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Pharmaceutical CDMO Historic Market Size by Region (2019-2024)
2.2.3 Pharmaceutical CDMO Forecasted Market Size by Region (2025-2030)
2.3 Pharmaceutical CDMO Market Dynamics
2.3.1 Pharmaceutical CDMO Industry Trends
2.3.2 Pharmaceutical CDMO Market Drivers
2.3.3 Pharmaceutical CDMO Market Challenges
2.3.4 Pharmaceutical CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Pharmaceutical CDMO Players by Revenue
3.1.1 Global Top Pharmaceutical CDMO Players by Revenue (2019-2024)
3.1.2 Global Pharmaceutical CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Pharmaceutical CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Pharmaceutical CDMO Revenue
3.4 Global Pharmaceutical CDMO Market Concentration Ratio
3.4.1 Global Pharmaceutical CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Pharmaceutical CDMO Revenue in 2023
3.5 Pharmaceutical CDMO Key Players Head office and Area Served
3.6 Key Players Pharmaceutical CDMO Product Solution and Service
3.7 Date of Enter into Pharmaceutical CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Pharmaceutical CDMO Breakdown Data by Type
4.1 Global Pharmaceutical CDMO Historic Market Size by Type (2019-2024)
4.2 Global Pharmaceutical CDMO Forecasted Market Size by Type (2025-2030)
5 Pharmaceutical CDMO Breakdown Data by Application
5.1 Global Pharmaceutical CDMO Historic Market Size by Application (2019-2024)
5.2 Global Pharmaceutical CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Pharmaceutical CDMO Market Size (2019-2030)
6.2 North America Pharmaceutical CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Pharmaceutical CDMO Market Size by Country (2019-2024)
6.4 North America Pharmaceutical CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Pharmaceutical CDMO Market Size (2019-2030)
7.2 Europe Pharmaceutical CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Pharmaceutical CDMO Market Size by Country (2019-2024)
7.4 Europe Pharmaceutical CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Pharmaceutical CDMO Market Size (2019-2030)
8.2 Asia-Pacific Pharmaceutical CDMO Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Pharmaceutical CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Pharmaceutical CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Pharmaceutical CDMO Market Size (2019-2030)
9.2 Latin America Pharmaceutical CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Pharmaceutical CDMO Market Size by Country (2019-2024)
9.4 Latin America Pharmaceutical CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Pharmaceutical CDMO Market Size (2019-2030)
10.2 Middle East & Africa Pharmaceutical CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Pharmaceutical CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Pharmaceutical CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Detail
11.1.2 Lonza Business Overview
11.1.3 Lonza Pharmaceutical CDMO Introduction
11.1.4 Lonza Revenue in Pharmaceutical CDMO Business (2019-2024)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Detail
11.2.2 Catalent Business Overview
11.2.3 Catalent Pharmaceutical CDMO Introduction
11.2.4 Catalent Revenue in Pharmaceutical CDMO Business (2019-2024)
11.2.5 Catalent Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Detail
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Pharmaceutical CDMO Introduction
11.3.4 Thermo Fisher Scientific Revenue in Pharmaceutical CDMO Business (2019-2024)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Samsung Biologics
11.4.1 Samsung Biologics Company Detail
11.4.2 Samsung Biologics Business Overview
11.4.3 Samsung Biologics Pharmaceutical CDMO Introduction
11.4.4 Samsung Biologics Revenue in Pharmaceutical CDMO Business (2019-2024)
11.4.5 Samsung Biologics Recent Development
11.5 Fareva
11.5.1 Fareva Company Detail
11.5.2 Fareva Business Overview
11.5.3 Fareva Pharmaceutical CDMO Introduction
11.5.4 Fareva Revenue in Pharmaceutical CDMO Business (2019-2024)
11.5.5 Fareva Recent Development
11.6 WuXi AppTech
11.6.1 WuXi AppTech Company Detail
11.6.2 WuXi AppTech Business Overview
11.6.3 WuXi AppTech Pharmaceutical CDMO Introduction
11.6.4 WuXi AppTech Revenue in Pharmaceutical CDMO Business (2019-2024)
11.6.5 WuXi AppTech Recent Development
11.7 WuXi Biologics
11.7.1 WuXi Biologics Company Detail
11.7.2 WuXi Biologics Business Overview
11.7.3 WuXi Biologics Pharmaceutical CDMO Introduction
11.7.4 WuXi Biologics Revenue in Pharmaceutical CDMO Business (2019-2024)
11.7.5 WuXi Biologics Recent Development
11.8 Siegfried
11.8.1 Siegfried Company Detail
11.8.2 Siegfried Business Overview
11.8.3 Siegfried Pharmaceutical CDMO Introduction
11.8.4 Siegfried Revenue in Pharmaceutical CDMO Business (2019-2024)
11.8.5 Siegfried Recent Development
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Detail
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Pharmaceutical CDMO Introduction
11.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Pharmaceutical CDMO Business (2019-2024)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.10 Asymchem
11.10.1 Asymchem Company Detail
11.10.2 Asymchem Business Overview
11.10.3 Asymchem Pharmaceutical CDMO Introduction
11.10.4 Asymchem Revenue in Pharmaceutical CDMO Business (2019-2024)
11.10.5 Asymchem Recent Development
11.11 Pfizer CentreOne
11.11.1 Pfizer CentreOne Company Detail
11.11.2 Pfizer CentreOne Business Overview
11.11.3 Pfizer CentreOne Pharmaceutical CDMO Introduction
11.11.4 Pfizer CentreOne Revenue in Pharmaceutical CDMO Business (2019-2024)
11.11.5 Pfizer CentreOne Recent Development
11.12 Delpharm
11.12.1 Delpharm Company Detail
11.12.2 Delpharm Business Overview
11.12.3 Delpharm Pharmaceutical CDMO Introduction
11.12.4 Delpharm Revenue in Pharmaceutical CDMO Business (2019-2024)
11.12.5 Delpharm Recent Development
11.13 Recipharm
11.13.1 Recipharm Company Detail
11.13.2 Recipharm Business Overview
11.13.3 Recipharm Pharmaceutical CDMO Introduction
11.13.4 Recipharm Revenue in Pharmaceutical CDMO Business (2019-2024)
11.13.5 Recipharm Recent Development
11.14 AGC Pharma Chemicals
11.14.1 AGC Pharma Chemicals Company Detail
11.14.2 AGC Pharma Chemicals Business Overview
11.14.3 AGC Pharma Chemicals Pharmaceutical CDMO Introduction
11.14.4 AGC Pharma Chemicals Revenue in Pharmaceutical CDMO Business (2019-2024)
11.14.5 AGC Pharma Chemicals Recent Development
11.15 Boehringer Ingelheim
11.15.1 Boehringer Ingelheim Company Detail
11.15.2 Boehringer Ingelheim Business Overview
11.15.3 Boehringer Ingelheim Pharmaceutical CDMO Introduction
11.15.4 Boehringer Ingelheim Revenue in Pharmaceutical CDMO Business (2019-2024)
11.15.5 Boehringer Ingelheim Recent Development
11.16 Vetter
11.16.1 Vetter Company Detail
11.16.2 Vetter Business Overview
11.16.3 Vetter Pharmaceutical CDMO Introduction
11.16.4 Vetter Revenue in Pharmaceutical CDMO Business (2019-2024)
11.16.5 Vetter Recent Development
11.17 Curia
11.17.1 Curia Company Detail
11.17.2 Curia Business Overview
11.17.3 Curia Pharmaceutical CDMO Introduction
11.17.4 Curia Revenue in Pharmaceutical CDMO Business (2019-2024)
11.17.5 Curia Recent Development
11.18 Aenova
11.18.1 Aenova Company Detail
11.18.2 Aenova Business Overview
11.18.3 Aenova Pharmaceutical CDMO Introduction
11.18.4 Aenova Revenue in Pharmaceutical CDMO Business (2019-2024)
11.18.5 Aenova Recent Development
11.19 Porton
11.19.1 Porton Company Detail
11.19.2 Porton Business Overview
11.19.3 Porton Pharmaceutical CDMO Introduction
11.19.4 Porton Revenue in Pharmaceutical CDMO Business (2019-2024)
11.19.5 Porton Recent Development
11.20 Piramal
11.20.1 Piramal Company Detail
11.20.2 Piramal Business Overview
11.20.3 Piramal Pharmaceutical CDMO Introduction
11.20.4 Piramal Revenue in Pharmaceutical CDMO Business (2019-2024)
11.20.5 Piramal Recent Development
11.21 Strides Pharma
11.21.1 Strides Pharma Company Detail
11.21.2 Strides Pharma Business Overview
11.21.3 Strides Pharma Pharmaceutical CDMO Introduction
11.21.4 Strides Pharma Revenue in Pharmaceutical CDMO Business (2019-2024)
11.21.5 Strides Pharma Recent Development
11.22 NextPharma
11.22.1 NextPharma Company Detail
11.22.2 NextPharma Business Overview
11.22.3 NextPharma Pharmaceutical CDMO Introduction
11.22.4 NextPharma Revenue in Pharmaceutical CDMO Business (2019-2024)
11.22.5 NextPharma Recent Development
11.23 Famar
11.23.1 Famar Company Detail
11.23.2 Famar Business Overview
11.23.3 Famar Pharmaceutical CDMO Introduction
11.23.4 Famar Revenue in Pharmaceutical CDMO Business (2019-2024)
11.23.5 Famar Recent Development
11.24 Jubilant
11.24.1 Jubilant Company Detail
11.24.2 Jubilant Business Overview
11.24.3 Jubilant Pharmaceutical CDMO Introduction
11.24.4 Jubilant Revenue in Pharmaceutical CDMO Business (2019-2024)
11.24.5 Jubilant Recent Development
11.25 Alcami
11.25.1 Alcami Company Detail
11.25.2 Alcami Business Overview
11.25.3 Alcami Pharmaceutical CDMO Introduction
11.25.4 Alcami Revenue in Pharmaceutical CDMO Business (2019-2024)
11.25.5 Alcami Recent Development
11.26 Euroapi
11.26.1 Euroapi Company Detail
11.26.2 Euroapi Business Overview
11.26.3 Euroapi Pharmaceutical CDMO Introduction
11.26.4 Euroapi Revenue in Pharmaceutical CDMO Business (2019-2024)
11.26.5 Euroapi Recent Development
11.27 Eurofins
11.27.1 Eurofins Company Detail
11.27.2 Eurofins Business Overview
11.27.3 Eurofins Pharmaceutical CDMO Introduction
11.27.4 Eurofins Revenue in Pharmaceutical CDMO Business (2019-2024)
11.27.5 Eurofins Recent Development
11.28 Avid Bioservices
11.28.1 Avid Bioservices Company Detail
11.28.2 Avid Bioservices Business Overview
11.28.3 Avid Bioservices Pharmaceutical CDMO Introduction
11.28.4 Avid Bioservices Revenue in Pharmaceutical CDMO Business (2019-2024)
11.28.5 Avid Bioservices Recent Development
11.29 BioVectra
11.29.1 BioVectra Company Detail
11.29.2 BioVectra Business Overview
11.29.3 BioVectra Pharmaceutical CDMO Introduction
11.29.4 BioVectra Revenue in Pharmaceutical CDMO Business (2019-2024)
11.29.5 BioVectra Recent Development
11.30 CPL
11.30.1 CPL Company Detail
11.30.2 CPL Business Overview
11.30.3 CPL Pharmaceutical CDMO Introduction
11.30.4 CPL Revenue in Pharmaceutical CDMO Business (2019-2024)
11.30.5 CPL Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock